Diabetes and Dollars: Cost-of-Care Quiz
True or False: In 2015, Americans spent more on insulin glargine than any other drug. The answer and 9 more questions in our quiz. (Source: ConsultantLive)
Source: ConsultantLive - July 26, 2018 Category: Internal Medicine Authors: Grace Halsey Tags: Diabetes Source Type: news
Insulin Glargine 300 Safe, Effective in Seniors With T2DM
TUESDAY, June 26, 2018 -- For older adults, insulin glargine 300 units/mL (Gla-300) is safe and as effective as Gla-100, with a similarly low or lower risk of symptomatic hypoglycemia, according to a study published online June 12 in Diabetes... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 26, 2018 Category: Pharmaceuticals Source Type: news
Toujeo (Insulin Glargine Injection for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 9, 2018 Category: Drugs & Pharmacology Source Type: news
FDA approves Toujeo(R) Max SoloStar(R)
Max SoloStar holds more insulin than any other long-acting insulin pen
New pen can potentially reduce the number of injections for people who need more long-acting insulin and lower copay costs
BRIDGEWATER, N.J., March 27, 2018 -- (Healthcare Sales &... Biopharmaceuticals, Drug Delivery, FDA Sanofi, Toujeo, insulin glargine, insulin pen, insulin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2018 Category: Pharmaceuticals Source Type: news
Sanofi ’ s high-capacity insulin pen wins FDA nod
Sanofi (NYSE:SNY) reported today that its Toujeo Max SoloStar high-capacity insulin pen won FDA approval and will be available in the third quarter of this year.
The new device holds 900 units of long-acting insulin and delivers 160 units/mL of Toujeo insulin glargine in each injection, the insulin-maker touted.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi’s high-capacity insulin pen wins FDA nod appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 27, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Sanofi-Aventis Source Type: news
FDA Approves Toujeo (insulin glargine) Max SoloStar
BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Sanofi ' s Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 27, 2018 Category: Drugs & Pharmacology Source Type: news
FDA approves label update to Novo Nordisk ’s Tresiba diabetes drug
The FDA approved Novo Nordisk‘s (NYSE:NVO) request to include heart health data on the label of its Tresiba insulin degludec product.
The Danish insulin-maker evaluated its Type II diabetes drug in a 7,637-patient trial, assessing the therapy for cardiovascular safety compared to insulin glargine.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves label update to Novo Nordisk’s Tresiba diabetes drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news
FDA approves inclusion of data from safety outcomes trial in the Tresiba(R) label
The data showed that Tresiba® (insulin degludec injection) U-100 had no increased risk of MACE compared to insulin glargine U-100 in patients with type 2 diabetes and ASCVD1
Tresiba® U-100 becomes the first and only long-acting insulin to have d... Biopharmaceuticals, Endocrinology, Cardiology, FDA Novo Nordisk, Tresiba, insulin degludec, insulin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2018 Category: Pharmaceuticals Source Type: news
Sanofi touts real-world data for Toujeo insulin glargine injection
Sanofi (NYSE:SNY) touted data today from its 10,000-patient Lightning study, which evaluated electronic medical records of adults with Type II diabetes to study its long-acting insulin glargine injection, Toujeo.
The company found that Toujeo significantly lowered patients’ risk of experiencing severe low blood sugar compared to other long-acting insulin, like its own Lantus product.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi touts real-world data for Toujeo insulin glargine injection appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Sanofi-Aventis Source Type: news
FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer
[1-12-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 7, 2018 Category: Drugs & Pharmacology Source Type: news
European committee backs Mylan ’ s insulin glargine biosimilar
Mylan (NSDQ:MYL) and Biocon announced today that a European Medicines Agency committee has recommended approval for its biosimilar insulin glargine, Semglee.
The committee’s positive opinion brings the product one step closer to approval. The European Commission is slated to make a final decision in April.
Get the full story at our sister site, Drug Delivery Business News.
The post European committee backs Mylan’s insulin glargine biosimilar appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Pharmaceuticals Regulatory/Compliance Wall Street Beat biocon Mylan Source Type: news
Sanofi, Facing Threat from Generics, Moves to Buy Hemophilia Drug Maker
The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant ’ s portfolio as it faces falling sales for its diabetes drug, Lantus. (Source: NYT Health)
Source: NYT Health - January 22, 2018 Category: Consumer Health News Authors: CHAD BRAY Tags: Mergers, Acquisitions and Divestitures Drugs (Pharmaceuticals) Hemophilia Sanofi SA Brandicourt, Olivier Source Type: news
Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus(R) Patents
HERTFORDSHIRE, England and PITTSBURGH, Dec. 14, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings on... Biopharmaceuticals, Generics, Litigation Mylan, Sanofi, Lantus, insulin glargine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2017 Category: Pharmaceuticals Source Type: news
Appeal board to review Sanofi ’ s Lantus insulin injection patents
The U.S. Patent and Trademark Appeal Board has instituted inter partes review on all claims against two patents owned by Sanofi (NYSE:SNY) for the company’s Lantus insulin glargine injection.
Sanofi filed a patent infringement suit against Mylan (NSDQ:MYL) in October after the EpiPen-maker submitted an NDA for a pre-filled insulin glargine pen, challenging the patents listed for Sanofi’s Lantus products.
Get the full story at our sister site, Drug Delivery Business News.
The post Appeal board to review Sanofi’s Lantus insulin injection patents appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Merck Mylan Sanofi-Aventis Source Type: news
Sanofi touts head-to-head comparison of long-acting insulin products
Sanofi‘s (NYSE:SNY) long-acting insulin glargine, Toujeo, met the primary objective of a head-to-head trial comparing it to Novo Nordisk‘s (NYSE:NVO) insulin degludec, Tresiba, the company reported today.
The insulin-maker said it plans to report full results from the Bright trial sometime next year. The study’s primary objective was to determine if Toujeo had a similar effect on blood sugar levels compared to insulin degludec.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi touts head-to-head comparison of long-acting insulin products appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 4, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Novo Nordisk Sanofi-Aventis Source Type: news
